Treatment-emergent adverse events after infusion of adherent stem cells: The MiSOT-I score for solid organ transplantation

Trials

Volumn 13, Issue , 2012, Pages

  Dillmann, Johannes ^a   Popp, Felix C ^a   Fillenberg, Barbara ^a   Zeman, Florian ^a   Eggenhofer, Elke ^a   Farkas, Stefan ^a   Scherer, Marcus N ^a   Koller, Michael ^a   Geissler, Edward K ^a   Deans, Robert ^b   Ladenheim, Deborah ^b   Loss, Martin ^a   Schlitt, Hans J ^a   Dahlke, Marc H ^a  

^a UNIVERSITY HOSPITAL REGENSBURG   (Germany)

^b ATHERSYS INC   (United States)

Author keywords

Adherent adult stem cells; Immunotherapy; Mesenchymal stem cells; Multipotent adult progenitor cells; Phase I trial; Scoring adverse events; Solid organ transplantation

Indexed keywords

CYCLOSPORIN A; RAPAMYCIN; TACROLIMUS;

ADULT; ADVERSE OUTCOME; AGED; ALLOTRANSPLANTATION; ANAPHYLAXIS; ARTICLE; ARTIFICIAL VENTILATION; CLINICAL ASSESSMENT TOOL; CLINICAL OBSERVATION; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; GRAFT RECIPIENT; GRAFT REJECTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFUSION RELATED REACTION; LIVER TRANSPLANTATION; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MISOT-I SCORE; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; RETROSPECTIVE STUDY; SCORING SYSTEM; SHOCK; STEM CELL TRANSPLANTATION;

ADULT; CHI-SQUARE DISTRIBUTION; DECISION SUPPORT TECHNIQUES; DISEASE-FREE SURVIVAL; FEMALE; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KAPLAN-MEIER ESTIMATE; LIVER TRANSPLANTATION; LUNG DISEASES; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; PREDICTIVE VALUE OF TESTS; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; SEVERITY OF ILLNESS INDEX; STEM CELL TRANSPLANTATION; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84868709577     PISSN: None     EISSN: 17456215     Source Type: Journal    
DOI: 10.1186/1745-6215-13-211     Document Type: Article

References (39)

1. Dutkowski P, Oberkofler CE, Béchir M, Müllhaupt B, Geier A, Raptis DA, Clavien PA. The model for end-stage liver disease allocation system for liver transplantation saves lives, but increases morbidity and cost: a prospective outcome analysis. Liver Transpl 2011, 17:674-684. 10.1002/lt.22228, 21618688.
2. Cattaneo D, Perico N, Gaspari F, Remuzzi G. Nephrotoxic aspects of cyclosporine. Transplant Proc 2004, 36:234S-239S. 10.1016/j.transproceed.2004.01.011, 15041344.
3. Vajdic CM, van Leeuwen MT. Cancer incidence and risk factors after solid organ transplantation. Int J Cancer 2009, 125:1747-1754. 10.1002/ijc.24439, 19444916.
4. Fulginiti VA, Scribner R, Groth CG, Putnam CW, Brettschneider L, Gilbert S, Porter KA, Starzl TE. Infections in recipients of liver homografts. N Engl J Med 1968, 279:619-626. 10.1056/NEJM196809192791202, 2772060, 4299208.
5. Jiang Y, Jahagirdar BN, Reinhardt RL, Schwartz RE, Keene CD, Ortiz- Gonzalez XR, Reyes M, Lenvik T, Lund T, Blackstad M, Du J, Aldrich S, Lisberg A, Low WC, Largaespada DA, Verfaillie CM. Pluripotency of mesenchymal stem cells derived from adult marrow. Nature 2002, 418:41-49. 10.1038/nature00870, 12077603.
6. Reyes M, Verfaillie CM. Characterization of multipotent adult progenitor cells, a subpopulation of mesenchymal stem cells. Ann N Y Acad Sci 2001, 938:231-233. discussion 233-235.
7. English K, French A, Wood KJ. Mesenchymal stromal cells: facilitators of successful transplantation?. Cell Stem Cell 2010, 7:431-442. 10.1016/j.stem.2010.09.009, 20887949.
8. Popp FC, Eggenhofer E, Renner P, Slowik P, Lang SA, Kaspar H, Geissler EK, Piso P, Schlitt HJ, Dahlke MH. Mesenchymal stem cells can induce long-term acceptance of solid organ allografts in synergy with low- dose mycophenolate. Transpl Immunol 2008, 20:55-60. 10.1016/j.trim.2008.08.004, 18762258.
9. Ge W, Jiang J, Baroja ML, Arp J, Zassoko R, Liu W, Bartholomew A, Garcia B, Wang H. Infusion of mesenchymal stem cells and rapamycin synergize to attenuate alloimmune responses and promote cardiac allograft tolerance. Am J Transplant 2009, 9:1760-1772. 10.1111/j.1600-6143.2009.02721.x, 19563344.
10. Popp FC, Fillenberg B, Eggenhofer E, Renner P, Dillmann J, Benseler V, Schnitzbauer AA, Hutchinson J, Deans R, Ladenheim D, Graveen C, Zeman F, Koller M, Hoogduijn MJ, Geissler EK, Schlitt HJ, Dahlke MH. Study protocol: Safety and feasibility of third-party multipotent adult progenitor cells for immunomodulation therapy after liver transplantation-a phase I study (MISOT-I). J Trans Med 2011, 9:124.
11. Newcombe RG. Two-sided confidence intervals for the single proportion: comparison of seven methods. Stat Med 1998, 17:857-872. 10.1002/(SICI)1097-0258(19980430)17:8<857::AID-SIM777>3.0.CO;2-E, 9595616.
12. Ramot Y, Steiner M, Morad V, Leibovitch S, Amouyal N, Cesta MF, Nyska A. Pulmonary thrombosis in the mouse following intravenous administration of quantum dot-labeled mesenchymal cells. Nanitoxicology 2010, 4:98-105.
13. Furlani D, Ugurlucan M, Ong L, Bieback K, Pittermann E, Westien I, Wang W, Yerebakan C, Li W, Gaebel R, Li RK, Vollmar B, Steinhoff G, Ma N. Is the intravascular administration of mesenchymal stem cells safe? Mesenchymal stem cells and intravital microscopy. Microvasc Res 2009, 77:370-376. 10.1016/j.mvr.2009.02.001, 19249320.
14. Dimomeletis I, Deindl E, Zaruba M, Groebner M, Zahler S, Laslo SM, David R, Kostin S, Deutsch MA, Assmann G, Mueller-Hoecker J, Feuring-Buske M, Franz WM. Assessment of human MAPCs for stem cell transplantation and cardiac regeneration after myocardial infarction in SCID mice. Exp Hematol 2010, 38:1105-1114. 10.1016/j.exphem.2010.06.013, 20621157.
15. Trounson A, Thakar RG, Lomax G, Gibbons D. Clinical trials for stem cell therapies. BMC Med 2011, 10:9-52.
16. Gonsalves A, Carrier M, Wells PS, McDiarmid SA, Huebsch LB, Allan DS. Incidence of symptomatic venous thromboembolism following hematopoietic stem cell transplantation. J Thromb Haemost 2008, 6:1468-1473. 10.1111/j.1538-7836.2008.03077.x, 18627443.
17. Bernard G, Artigas A, Brigham K, Carlet J, Falke K, Hudson L, Lamy M, Legall J, Morris A, Spragg R. The American-European Consensus Conference on ARDS. Definitions, mechanisms, relevant outcomes, and clinical trial coordination. Am J Respir Crit Care Med 1994, 149:818-824.
18. Faenza S, Ravaglia MS, Cimatti M, Dante A, Spedicato S, Morselli Labate AM. Analysis of the causal factors of prolonged mechanical ventilation after orthotopic liver transplant. Transplant Proc 2006, 38:1131-1134. 10.1016/j.transproceed.2006.03.055, 16757286.
19. Skurzak S, Stratta C, Schellino MM, Fop F, Andruetto P, Gallo M, Rampa P, Crucitti M, Zabatta D, Panio A, Cerutti E. Extubation score in the operating room after liver transplantation. Acta Anaesthesiol Scand 2010, 54:970-978. 10.1111/j.1399-6576.2010.02274.x, 20626358.
20. Torbicki A, Perrier A, Konstantinides S, Agnelli G, Galie N, Pruszczyk P, Bengel F, Brady AJ, Ferreira D, Janssens U, Klepetko W, Mayer E, Remy-Jardin M, Bassand JP, . ESC Committee for Practice Guidelines (CPG) Guidelines on the diagnosis and management of acute pulmonary embolism: the Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). Eur Heart J 2008, 29:2276-2315. ESC Committee for Practice Guidelines (CPG).
21. Mullan CP, Siewert B, Kane RA, Sheiman RG. Can Doppler sonography discern between hemodynamically significant and insignificant portal vein stenosis after adult liver transplantation?. AJR Am J Roentgenol 2010, 195:1438-1443. 10.2214/AJR.10.4636, 21098207.
22. Nakanishi S, Shiraki K, Yamamoto K, Saitou Y, Ohmori S, Nakano T, Mizuno S, Tabata M, Yamagiwa K, Yokoi H, Isaji S, Uemoto S. Early graft hemodynamics in living related liver transplantation evaluated by Doppler ultrasonography. Int J Mol Med 2004, 14:265-269.
23. Dodd GD, Memel DS, Zajko AB, Baron RL, Santaguida LA. Hepatic artery stenosis and thrombosis in transplant recipients: Doppler diagnosis with resistive index and systolic acceleration time. Radiology 1994, 192:657-661.
24. Chen W, Facciuto ME, Rocca JP, Marvin MR, Sheiner PA, Rachlin S, Rodriguez MI. Doppler ultrasonographic findings on hepatic arterial vasospasms early after liver transplantation. J Ultrasound Med 2006, 25:631-638.
25. Ko EY, Kim TK, Kim PN, Kim AY, Ha HK, Lee MG. Hepatic vein stenosis after living donor liver transplantation: evaluation with Doppler US. Radiology 2003, 229:806-810. 10.1148/radiol.2293020700, 14576444.
26. Tamsel S, Demirpolat G, Killi R, Aydin U, Kilic M, Zeytunlu M, Parildar M, Oran I, Ucar H. Vascular complications after liver transplantation: evaluation with Doppler US. Abdom Imaging 2007, 32:339-347. 10.1007/s00261-006-9041-z, 16967253.
27. Sampson HA, Muñoz-Furlong A, Campbell RL, Adkinson NF, Bock SA, Branum A, Brown SG, Camargo CA, Cydulka R, Galli SJ, Gidudu J, Gruchalla RS, Harlor AD, Hepner DL, Lewis LM, Lieberman PL, Metcalfe DD, O'Connor R, Muraro A, Rudman A, Schmitt C, Scherrer D, Simons FE, Thomas S, Wood JP, Decker WW. Second symposium on the definition and management of anaphylaxis: Summary report--Second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network symposium. Ann Emerg Med 2006, 47:373-380. 10.1016/j.annemergmed.2006.01.018, 16546624.
28. Cherian TP, Chiu K, Gunson B, Bramhall SR, Mayer D, Mirza DF, Buckels JA. Pulmonary thromboembolism in liver transplantation: a retrospective review of the first 25 years. Transpl Int 2010, 23:1113-1119. 10.1111/j.1432-2277.2010.01105.x, 20497402.
29. Li SR, Shen N, Hei ZQ. Early risk factors of acute lung injury following orthotopic liver transplantation. Zhonghua Yi Xue Za Zhi 2008, 88:3049-3052.
30. Pareja E, Cortes M, Navarro R, Sanjuan F, López R, Mir J. Vascular complications after orthotopic liver transplantation: hepatic artery thrombosis. Transplant Proc 2010, 42:2970-2972. 10.1016/j.transproceed.2010.07.063, 20970585.
31. Wu L, Zhang J, Guo Z, Tai Q, He X, Ju W, Wang D, Zhu X, Ma Y, Wang G, Hu A. Hepatic artery thrombosis after orthotopic liver transplant: a review of the same institute 5 years later. Exp Clin Transplant 2011, 9:191-196.
32. Andersona A, Eilersa H, Spencer Yost C. Anaphylaxis complicating graft reperfusion during orthotopic liver transplantation: a case report. Transplant Proc 2010, 42:1967-1969. 10.1016/j.transproceed.2010.03.135, 20620557.
33. Jaeck D, Fratte S, Boudjema K, Ellero B, Woehl-Jaegle ML, Vanlemmens C, Altier M, Duclos B, Vetter D, Bachellier P. Comparative study of results of hepatic transplantation between 2 groups of patients: alcoholic cirrhosis versus non-alcoholic cirrhosis. Chirurgie 1993-1994, 119:569-573.
34. Weismüller TJ, Prokein J, Becker T, Barg-Hock H, Klempnauer J, Manns MP, Strassburg CP. Prediction of survival after liver transplantation by pre-transplant parameters. Scand J Gastroenterol 2008, 43:736-746. 10.1080/00365520801932944, 18569992.
35. Matinlauri IH, Nurminen MM, Höckerstedt KA, Isoniemi HM. Risk factors predicting survival of liver transplantation. Transplant Proc 2005, 37:1155-1160. 10.1016/j.transproceed.2004.12.078, 15848655.
36. Sumskiene J, Kupcinskas L, Pundzius J, Sumskas L. Prognostic factors for short and long-term survival in patients selected for liver transplantation. Medicina (Kaunas) 2005, 41:39-46.
37. Totsuka E, Fung JJ, Hakamada K, Ohashi M, Takahashi K, Nakai M, Morohashi S, Morohashi H, Kimura N, Nishimura A, Ishizawa Y, Ono H, Narumi S, Sasaki M. Synergistic effect of cold and warm ischemia time on postoperative graft function and outcome in human liver transplantation. Transplant Proc 2004, 36:1955-1958. 10.1016/j.transproceed.2004.08.068, 15518710.
38. Cholongitas E, Marelli L, Shusang V, Senzolo M, Rolles K, Patch D, Burroughs AK. A systematic review of the performance of the model for end-stage liver disease (MELD) in the setting of liver transplantation. Liver Transpl 2006, 12:1049-1061. 10.1002/lt.20824, 16799946.
39. Goralczyk AD, Schnitzbauer A, Tsui TY, Ramadori G, Lorf T, Obed A. A therapeutic exploratory study to determine the efficacy and safety of calcineurin-inhibitor-free de-novo immunosuppression after liver transplantation: CILT. BMC Surg 2010, 10:15. 10.1186/1471-2482-10-15, 2858131, 20380712.